Sera Prognostics Completes Enrollment of Large, Multicenter, Prospective Clinical Study of PreTRM® Test
November 27, 2018 08:00 ET
|
Sera Prognostics, Inc.
TREETOP Study will Explore Enhancements to Sera’s Validated PreTRM® Test SALT LAKE CITY, Nov. 27, 2018 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women’s health company, announced today that...
Lexington Provides Q3 Corporate Review
October 23, 2018 18:37 ET
|
Lexington Biosciences, Inc.
VANCOUVER, British Columbia, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is...
MSI Methylation Sciences, Inc. (MSI) provides an update on its corporate activities, including its recent arbitration award of $20 million USD against Quark Venture Inc (Quark)
October 18, 2018 07:06 ET
|
MSI Methylation Sciences
BURNABY, B.C., Oct. 18, 2018 (GLOBE NEWSWIRE) -- In a January 2016 press release, MSI announced the results of its first Phase 2 clinical trial designed to evaluate the efficacy and safety of...
VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
October 16, 2018 08:00 ET
|
VBI Vaccines, Inc.
Vaccination complete in 1,537 subjects in PROTECT Phase 3 studyNo vaccine-related adverse events have been observed to-dateTop-line data expected mid-2019 CAMBRIDGE, Mass., Oct. 16, 2018 (GLOBE...
VBI Vaccines’ Late-Breaker Cytomegalovirus Abstract Chosen for Oral Presentation at IDWeek 2018
October 02, 2018 08:00 ET
|
VBI Vaccines, Inc.
Presentation to feature complete safety and immunogenicity dataset from the Phase 1 clinical study of VBI-1501Oral presentation at IDWeek 2018 on Saturday, October 6th, 2018, at 11:10 AM PDT ...
VBI Vaccines Announces Second Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients
September 25, 2018 08:00 ET
|
VBI Vaccines, Inc.
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modificationIntermediate-dose study arm: enrollment complete Initial immunologic data from low...
Publication of eQUEST Study Results Demonstrate that eSight 3 is a Clinically Effective Device for the Visually Impaired
September 04, 2018 12:56 ET
|
eSight
TORONTO and LOS ANGELES, Sept. 04, 2018 (GLOBE NEWSWIRE) -- Dr. Brian Mech, President and CEO of eSight, is proud to announce the publication of results from eQUEST (The eSight Quality of Life and...
Biomerica Announces Fiscal Year End 2018 Financial Results
August 30, 2018 08:19 ET
|
Biomerica, Inc.
IRVINE, Calif., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported net sales for the fiscal year 2018 were $5,564,185...
Cognoa Demonstrates Advances of its AI-Based Technology for Identifying Autism in Children
August 27, 2018 13:49 ET
|
Cognoa
PALO ALTO, Calif., Aug. 27, 2018 (GLOBE NEWSWIRE) -- Cognoa, a digital behavioral health company, today announces results from a clinical study of its second-generation AI based algorithms which...
InspireMD Reports on Expanded 2 Year Follow-up Results from the PARADIGM Clinical Study Using CGuard EPS
May 30, 2018 07:31 ET
|
InspireMD, Inc.
Results Presented at EuroPCR 2018 Confirm Sustained Safety and Cerebral Embolic Prevention out to 24 months TEL AVIV, ISRAEL, May 30, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE...